SB-T-1214
SB-T-1214 (SBT) is a taxane. SB-T-1214 efficiently inhibits expression of stem cell-related genes (Oct4, Sox2, and c-Myc) and induces apoptosis of colon cancer spheroids with drug resistant tumorigenic CD133+/CD44+ cells. SB-T-1214 strongly represses tumor growth in Pgp+ DLD-1 human colon tumor xenografts mice model. SB-T-1214 can be used for antitumor research, especially against tumors with drug resistance, such as colon, pancreatic and renal cancers.
For research use only. We do not sell to patients.
- CAS No.: 178250-23-2
- Formula: C45H59NO15
- Molecular Weight:853.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 1A9 | IC50 |
5 nM
Compound: SB-T-1214
|
Cytotoxicity against human 1A9 cells by MTT assay
Cytotoxicity against human 1A9 cells by MTT assay
|
[PMID: 25047938] |
| 1A9/ptx-10 | IC50 |
10.8 nM
Compound: SB-T-1214
|
Cytotoxicity against human 1A9PTX10 cells by MTT assay
Cytotoxicity against human 1A9PTX10 cells by MTT assay
|
[PMID: 25047938] |
| 1A9/ptx-10 | IC50 |
9 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs
Cytotoxicity against paclitaxel resistant human 1A9PTX10 cells expressing class 1 beta-tubulin mutant after 72 hrs
|
[PMID: 18465846] |
| 1A9/ptx-10 | IC50 |
9 nM
Compound: SB-T-1214
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs
Cytotoxicity against paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin after 72 hrs
|
[PMID: 19239240] |
| 1A9/ptx-22 | IC50 |
3.94 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs
Cytotoxicity against paclitaxel resistant human 1A9PTX22 cells expressing class 1 beta-tubulin mutant after 72 hrs
|
[PMID: 18465846] |
| 1A9/ptx-22 | IC50 |
3.94 nM
Compound: SB-T-1214
|
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs
Cytotoxicity against paclitaxel-resistant human 1A9PTX22 cells harboring point mutation in beta-tubulin after 72 hrs
|
[PMID: 19239240] |
| 1A9/ptx-22 | IC50 |
7.9 nM
Compound: SB-T-1214
|
Cytotoxicity against human 1A9PTX22 cells by MTT assay
Cytotoxicity against human 1A9PTX22 cells by MTT assay
|
[PMID: 25047938] |
| A121 | IC50 |
0.26 nM
Compound: 4b
|
Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
|
[PMID: 8831755] |
| A2780 | IC50 |
0.44 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against human A2780 cells after 72 hrs
Cytotoxicity against human A2780 cells after 72 hrs
|
[PMID: 18465846] |
| A2780 | IC50 |
0.44 nM
Compound: SB-T-1214
|
Cytotoxicity against human A2780 cells after 72 hrs
Cytotoxicity against human A2780 cells after 72 hrs
|
[PMID: 19239240] |
| A2780 | IC50 |
20.4 nM
Compound: SB-T-1214
|
Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin
Resistance factor, ratio of IC50 for human A2780 cells to IC50 for paclitaxel-resistant human 1A9PTX10 cells harboring point mutation in beta-tubulin
|
[PMID: 19239240] |
| A2780 | IC50 |
5.2 nM
Compound: SB-T-1214
|
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
|
[PMID: 25047938] |
| A2780 ADR | IC50 |
10.9 nM
Compound: SB-T-1214
|
Cytotoxicity against human A2780AD cells by MTT assay
Cytotoxicity against human A2780AD cells by MTT assay
|
[PMID: 25047938] |
| A549 | IC50 |
0.57 nM
Compound: 4b
|
Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
|
[PMID: 8831755] |
| BXPC-3 | IC50 |
1.04 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against multidrug resistant human BxPC3 cells after 72 hrs by MTT assay
Cytotoxicity against multidrug resistant human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 18465846] |
| BXPC-3 | IC50 |
1.04 nM
Compound: SB-T-1214
|
Cytotoxicity against human BxPC3 cells expressing mrp1, mrp2, lrp genes after 72 hrs
Cytotoxicity against human BxPC3 cells expressing mrp1, mrp2, lrp genes after 72 hrs
|
[PMID: 19239240] |
| CFPAC-1 | IC50 |
0.83 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against multidrug resistant human CFPAC1 cells after 72 hrs by MTT assay
Cytotoxicity against multidrug resistant human CFPAC1 cells after 72 hrs by MTT assay
|
[PMID: 18465846] |
| CFPAC-1 | IC50 |
0.83 nM
Compound: SB-T-1214
|
Cytotoxicity against human Cf-Pac-1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
Cytotoxicity against human Cf-Pac-1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
|
[PMID: 19239240] |
| HCT-116 | IC50 |
0.28 nM
Compound: 1; SB-T-1214
|
Cytotoxicity against CD133 positive human HCT116 cells
Cytotoxicity against CD133 positive human HCT116 cells
|
[PMID: 29468872] |
| HeLa | IC50 |
11.2 nM
Compound: SB-T-1214
|
Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay
Cytotoxicity against human HeLa cells transfected with wild-type tubulin beta3 by MTT assay
|
[PMID: 25047938] |
| HeLa | IC50 |
2.1 nM
Compound: SB-T-1214
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 25047938] |
| HEY | IC50 |
0.58 μM
Compound: SB-T-1214
|
Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
Cytotoxicity against human HEY cells after 72 to 120 hrs by sulforhodamine B assay
|
[PMID: 29517223] |
| HT-29 | IC50 |
0.36 nM
Compound: 4b
|
Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.
Concentration required to inhibit growth of human tumor HT-29 (colon) cell line.
|
[PMID: 8831755] |
| L1210 | IC50 |
2.66 nM
Compound: SB-T-1214
|
Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor over-expressing mouse L1210 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
| MCF7 | IC50 |
0.2 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
|
[PMID: 18465846] |
| MCF7 | IC50 |
0.2 nM
Compound: 4b
|
Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.
Concentration required to inhibit growth of human tumor MCF-7 (breast) cell line.
|
[PMID: 8831755] |
| MCF7 | IC50 |
0.2 nM
Compound: SB-T-1214
|
Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
|
[PMID: 19239240] |
| MCF7 | IC50 |
0.2 nM
Compound: SB-T-1214
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 25047938] |
| MCF7 | IC50 |
2.1 nM
Compound: 4b
|
Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.
Concentration required to inhibit growth of human tumor MFC7-R (breast) cell line.
|
[PMID: 8831755] |
| MCF7 | IC50 |
80.5 nM
Compound: 1; SB-T-1214
|
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human paclitaxel-resistant MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29468872] |
| MCF7R | IC50 |
2.1 nM
Compound: SB-T-1214
|
Cytotoxicity against human MCF7/R cells by MTT assay
Cytotoxicity against human MCF7/R cells by MTT assay
|
[PMID: 25047938] |
| MCF7R | IC50 |
3.9 nM
Compound: SB-T-1214
|
Cytotoxicity against human mammary tumor cell line MCF7-R
Cytotoxicity against human mammary tumor cell line MCF7-R
|
[PMID: 16298526] |
| MCF7S | IC50 |
0.2 nM
Compound: SB-T-1214
|
Cytotoxicity against human mammary tumor cell line MCF7-S
Cytotoxicity against human mammary tumor cell line MCF7-S
|
[PMID: 16298526] |
| MIA PaCa-2 | IC50 |
0.92 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against multidrug resistant human MIAPaCa2 cells after 72 hrs by MTT assay
Cytotoxicity against multidrug resistant human MIAPaCa2 cells after 72 hrs by MTT assay
|
[PMID: 18465846] |
| MIA PaCa-2 | IC50 |
0.92 nM
Compound: SB-T-1214
|
Cytotoxicity against human MIAPaCa2 cells expressing mrp1, mrp2, lrp genes after 72 hrs
Cytotoxicity against human MIAPaCa2 cells expressing mrp1, mrp2, lrp genes after 72 hrs
|
[PMID: 19239240] |
| MX1 | IC50 |
1.89 nM
Compound: SB-T-1214
|
Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor over-expressing human MX1 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
| PANC-1 | IC50 |
3.68 nM
Compound: 19, SB-T-1214
|
Cytotoxicity against multidrug resistant human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against multidrug resistant human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 18465846] |
| PANC-1 | IC50 |
3.68 nM
Compound: SB-T-1214
|
Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
Cytotoxicity against human PANC1 cells expressing mdr1, mrp1, mrp2, lrp genes after 72 hrs
|
[PMID: 19239240] |
| SK-OV-3 | IC50 |
0.62 nM
Compound: SB-T-1214
|
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs by sulforhodamine B assay
|
[PMID: 29517223] |
| SK-OV-3 | IC50 |
1.44 nM
Compound: SB-T-1214
|
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay
Cytotoxicity against human SKOV3 cells after 72 to 120 hrs in presence of verapamil by sulforhodamine B assay
|
[PMID: 29517223] |
| WI-38 | IC50 |
4.89 nM
Compound: SB-T-1214
|
Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay
Cytotoxicity against folate receptor deficient human WI38 cells after 72 hrs by MTT assay
|
[PMID: 25819334] |
SB-T-1214 (0.5-5000 nM, 72 h) has potent FR-specific anticancer activity with IC50s of 2.82, 1.89 , 2.66 and 4.89 nM for ID8, MX-1, L1210-FR and WI-38 cells[1].
SB-T-1214 (0.1-1 μM, 48 h) induces apoptosis in CSC-enriched colon cancer cells and spheroids with a loss of integrity of the floating spheroids and 1.5-3% secondary spheroids production in HCT116, HT29 and DLD-1 cells at 0.1 μM[2].
SB-T-1214 (0.1 μM, 24-24 h) significantly down-regulates a majority of the stemness genes such as SOX1, ACAN, and COL1A1 and inhibits the protein expression of pluripotency markers Oct4, Sox2, and c-Myc in spheroids from CD133+/CD44+ HCT116, HT29 and DLD-1 cells [2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:spheroids from CD133+/CD44+ HCT116 cells
-
Concentration:0.1 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the protein expression of pluripotency markers Oct4, Sox2, and c-Myc in spheroids from CD133+/CD44+ HCT116 cells.
-
Cell Line:spheroids from CD133+/CD44+ HCT116 cells
-
Concentration:0.1-1 μM
-
Incubation Time:48 h
-
Result:Induced a loss of integrity of the floating spheroids and apoptosis in more than 90% of the sphere cells.
Induced 89-96% CSC-enriched colon cancer cells apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice were injected subcutaneously with Pgp+ DLD-1 cells to induce Pgp+ DLD-1 human colon tumor xenografts mice model[1].
-
Dosage:10, 20, 40 mg/kg
-
Administration:i.v., q3d × 3 (day 5, 8, and 11).
-
Result:Had profound antitumor activity with 100% DLD-1 tumor regression 20 mg/kg and >201 days tumor growth delay.
Induced no significant toxicity with good tolerance and only a 3-5% weight loss during the period of day 15 to day 20.
Reduced tumor volume without expression human EpCAM and CD133.
Chemical Information
-
CAS No. 178250-23-2
-
Molecular Weight 853.95
-
Formula C45H59NO15
-
SMILES
CC(O[C@]12[C@@]3([H])[C@@H]([C@]4(C(C)(C([C@H](C([C@@]3([C@H](C[C@@]1([H])OC2)O)C)=O)OC(C5CC5)=O)=C([C@H](C4)OC([C@H](O)[C@H](/C=C(C)\C)NC(OC(C)(C)C)=O)=O)C)C)O)OC(C6=CC=CC=C6)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Seitz JD, et al. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate. Bioorg Med Chem. 2015 May 1; 23(9):2187-94. [Content Brief]
[2]. Botchkina GI, et al. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer. 2010 Jul 14; 9:192. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)